Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis
M Santoni, A Rizzo, J Kucharz, V Mollica… - Cancer Immunology …, 2023 - Springer
Background Immunotherapy has determined unprecedented long-term responses in several
hematological and solid tumors. In the MOUSEION-03 study, we conducted a meta-analysis …
hematological and solid tumors. In the MOUSEION-03 study, we conducted a meta-analysis …
Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Q Sun, Z Hong, C Zhang, L Wang, Z Han… - Signal transduction and …, 2023 - nature.com
Abstract Immune-checkpoint inhibitors (ICBs), in addition to targeting CTLA-4, PD-1, and PD-
L1, novel targeting LAG-3 drugs have also been approved in clinical application. With the …
L1, novel targeting LAG-3 drugs have also been approved in clinical application. With the …
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised …
J Wang, C Zhou, W Yao, Q Wang, X Min… - The Lancet …, 2022 - thelancet.com
Background Extensive-stage small-cell lung cancer (ES-SCLC) is associated with poor
prognosis and treatment options are scarce. Immunotherapy has shown robust clinical …
prognosis and treatment options are scarce. Immunotherapy has shown robust clinical …
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer …
JW Goldman, M Dvorkin, Y Chen, N Reinmuth… - The Lancet …, 2021 - thelancet.com
Background First-line durvalumab plus etoposide with either cisplatin or carboplatin
(platinum–etoposide) showed a significant improvement in overall survival versus platinum …
(platinum–etoposide) showed a significant improvement in overall survival versus platinum …
Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
AMC Dingemans, M Früh, A Ardizzoni… - Annals of …, 2021 - annalsofoncology.org
Small-cell lung cancer (SCLC) is the most aggressive form of lung cancer. Although SCLC is
characterised by rapid responses to chemotherapy (ChT) and sensitivity to radiotherapy …
characterised by rapid responses to chemotherapy (ChT) and sensitivity to radiotherapy …
The impact of gender on the efficacy of immune checkpoint inhibitors in cancer patients: the MOUSEION-01 study
M Santoni, A Rizzo, V Mollica, MR Matrana… - Critical Reviews in …, 2022 - Elsevier
The primary endpoint of MOUSEION-01 was to assess overall survival (OS) in male and
female patients receiving immune checkpoint inhibitors versus control treatments …
female patients receiving immune checkpoint inhibitors versus control treatments …
Antiemetics: ASCO guideline update
PJ Hesketh, MG Kris, E Basch, K Bohlke… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE To update the guideline to include new anticancer agents, antiemetics, and
antiemetic regimens and to provide recommendations on the use of dexamethasone as a …
antiemetic regimens and to provide recommendations on the use of dexamethasone as a …
Nivolumab and ipilimumab as maintenance therapy in extensive-disease small-cell lung cancer: CheckMate 451
TK Owonikoko, K Park, R Govindan… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE In extensive-disease small-cell lung cancer (ED-SCLC), response rates to first-
line platinum-based chemotherapy are robust, but responses lack durability. CheckMate …
line platinum-based chemotherapy are robust, but responses lack durability. CheckMate …
[HTML][HTML] First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer
L Horn, AS Mansfield, A Szczęsna… - … England Journal of …, 2018 - Mass Medical Soc
Background Enhancing tumor-specific T-cell immunity by inhibiting programmed death
ligand 1 (PD-L1)–programmed death 1 (PD-1) signaling has shown promise in the treatment …
ligand 1 (PD-L1)–programmed death 1 (PD-1) signaling has shown promise in the treatment …
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
Background Despite the acknowledged sex-related dimorphism in immune system
response, little is known about the effect of patients' sex on the efficacy of immune …
response, little is known about the effect of patients' sex on the efficacy of immune …